All In Biotech

Drug Trial Radar · NCT03567577

Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS

Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS - a Randomised, Placebo-controlled, Double-blind Trial

Last checked: Nov 19, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

92

Actual

Start

May 23, 2018

Primary completion

Dec 27, 2024

Study completion Dec 27, 2024

Sponsor

Sponsor type
Industry
First posted
Jun 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase IIb, randomized, placebo-controlled, double-blind, dose escalation study will assess the local and systemic safety of 7 days orally inhaled sequential multiple ascending doses of solnatide in patients with pulmonary permeability oedema and moderate-to-severe ARDS and review potential efficacy endpoints for a future phase III pivotal trial.

Conditions

  • ARDS

Interventions

  • Solnatide 25 mg powder for reconstitution for solution for inhalationDrug

    Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.

  • 0.9% Saline SolutionDrug

    Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety endpoint: Any cause deathTime frame: Randomisation - day 28
  2. Safety endpoint: Drug-related adverse eventsTime frame: Randomisation - day 14
  3. Safety endpoint: All adverse eventsTime frame: Randomisation - day 28

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Univ. Klinik für Innere Medizin / Gem. Einrichtung für Intensiv- und Notfallmedizin/GE Medizinische Universität Innsbruck

    Innsbruck, Austria

  • Department of Anesthesia, General Intensive Care and Pain Control,Medical University of Vienna

    Vienna, State of Vienna, Austria

  • Univ.-klinik f. Herz-, Thorax-, Gefäßchirurgische Anästhesiologie und lntensivmedizin, Medizinische Universität Graz

    Graz, Styria, Austria

  • Universitätsklinikum Bonn, Operative Intensivmedizin, Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin

    Bonn, Germany

  • Georg-August-Universität Göttingen

    Göttingen, Germany

  • Klinik für Anästhesiologie und operative Intensivmedizin, Universitätsklinikum Schleswig-Holstein, Campus Kiel,

    Kiel, Germany

  • Klinik für Anästhesiologie / Universitätsmedizin der Johannes Gutenberg-Universität Mainz

    Mainz, Germany

  • Klinik für Anästhesiologie und operative Intensivmedizin; Universitätsmedizin Mannheim

    Mannheim, Germany

  • Klinik für Anästhesiologie und Intensivmedizin; Klinikum rechts der Isar der TU München

    München, Germany

  • Klinik und Poliklinik für Innere Medizin II; Klinikum rechts der Isar der TU München

    München, Germany

  • Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie; Universitätsklinikum Münster

    Münster, Germany

  • Universitätsklinikum Würzburg, Klinik und Poliklinik für Anästhesiologie

    Würzburg, Germany

  • Klinik für Anaesthesiologie, Klinikum der Universität München, Campus Großhadern

    München, Bavaria, Germany

  • Klinik für Operative Intensivmedizin und Intermediate Care

    Aachen, North Rhine-Westphalia, Germany

  • Klinik und Poliklinik für Anästhesiologie und Intensivtherapie / Universitätsklinikum Carl Gustav Carus

    Dresden, Saxony, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.